NCT00428090 · Phase 3 · COMPLETED
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's disease. The idea was that if brain cells struggle to use glucose in AD, a drug that improves glucose processing might help. Phase 3 means this was a large, late-stage test of whether it actually works — not yet approved for this use.
You may qualify if
- Clinical diagnosis of probable Alzheimer's Disease (AD).
- MMSE score 10 to 23
- Has not taken an approved AD therapy in last 30 days.
- No previous hypersensitivity/intolerance to AChEIs
- Have a regular caregiver.
You're excluded if
- Diagnosis of vascular dementia.
- Type I or secondary diabetes mellitus.
- Type II diabetes mellitus treated with insulin, sulfonylurea or glipizide.
- History or evidence of congestive heart failure, clinically significant peripheral edema or anemia.
- History of significant psychiatric illness, major depressive disorder or current depression needing initiation of treatment.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2017-05-19